PD-1 Antikörper (Elab Fluor®700)

Produktnummer ABIN7566874

Dieses Anti-PD-1-Antikörper ist ein Ratte Monoklonal-Antikörper zur Detektion von PD-1 in FACS. Geeignet für Maus.

Kurzübersicht für PD-1 Antikörper (Elab Fluor®700) (ABIN7566874)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser PD-1 Antikörper ist konjugiert mit Elab Fluor®700

Applikation: Flow Cytometry (FACS)

Klon: 29F-1A12

Produktdetails anti-PD-1 Antikörper (Elab Fluor®700)

Verwendungszweck: Elab Fluor®700 Anti-Mouse CD279/PD-1 Antibody[29F.1A12]

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Each lot of this antibody is quality control tested by flow cytometric analysis. Applications vary, the appropriate dilutions must be determined for individual use.

Kommentare:

Matching Isotype Control: E-AB-F09832M1

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Phosphate buffered solution, pH 7.2, containing 0.09 % stabilizer and 1 % protein protectant.

Lagerung: 4 °C

Informationen zur Lagerung: This product can be stored at 2-8°C for 12 months. Please protected from prolonged exposure to light and do not freeze.

Haltbarkeit: 12 months

Details zu PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Andere Bezeichnung: CD279/PD-1

Hintergrund: Programmed Death-1,PD-1,CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Gen-ID: 18566

UniProt: Q02242

Pathways: Cancer Immune Checkpoints